5.3.2026 08:45:01 CET | Monsenso |
Årsrapport
Selskabsmeddelelse nr. 01-2026
København den 5. marts 2026
Monsensos årsrapport for 2025 blev godkendt af bestyrelsen i dag.
Hovedpunkter
Omsætning faldt med 20% til TDKK 8.907 (2024: TDKK 11.165)
Primært driftsresultat (EBITDA) var på TDKK -2.961 (2024: TDKK -2.053)
Driftsresultatet (EBIT) var på TDKK -7.582 (2024: TDKK -6.481)
Pengestrømme fra driftsaktivitet udgjorde TDKK -1.490 (2024: TDKK -7.033)
Egenkapitalen pr. 31. december 2025 var på TDKK 6.976 (2024: TDKK 14.164)
Likvide beholdninger pr. 31. december 2025 var på TDKK 54 (2024: TDKK 1.861)
Udvikling i forretningen
Året 2025 bød på betydelige udfordringer, da forsinkelser i vigtige strategiske projekter påvirkede omsætningen og det finansielle resultat for året. Især i Danmark hæmmede markedsforholdene fremskridt med et skift mod proprietære løsninger i den offentlige sundhedssektor. I Spanien blev et forventet projekt forsinket på grund af en klage over udvælgelsen af leverandører, hvilket efterfølgende resulterede i et betydeligt reduceret omfang af projektet.
Trods disse forhindringer fortsatte vi med at engagere os i lovende projekter, og der er fremdrift i alle igangværende innovations- og forskningsprojekter.
Især har samarbejdet om PhaseV med fremtrædende partnere fremmet en løsning til decentraliserede studier. Rekruttering af deltagere i PhaseV er afsluttet i et studie og to andre studier er i gang. Et fuldt decentraliseret hovedpinestudie baseret på vores platform i samarbejde med Lundbeck og Nationalt Videnscenter for Hovedpine er afsluttet med succes, og de første publikationer er udkommet.
Derudover er der fremdrift i det randomiserede kontrollerede forsøg i PERSONAE-projektet, der fokuserer på personlig AI- og data-dreven behandling. Mentbest-projektet, der er rettet mod mental sundhed gennem et AI-drevet selvhjælpsværktøj, rekrutterer aktivt deltagere i flere europæiske lande.
Vi mener fortsat, at markederne for digital sundhed inden for mental sundhed og kroniske lidelser i Europa er attraktive drevet af behovet for effektivitet i de europæiske sundhedssystemer. Når vi går ind i 2026, ser vi store muligheder for at vækste forretningen igen drevet af enkelte større projekter.
CEO Thomas Lethenborg udtaler:
“Digital sundhed står bestemt højt på dagsordenen hos både offentlige og private udbydere, forskningsinstitutioner og lægemiddelvirksomheder. Der er en voksende erkendelse af, at kombinationen af løbende indsamling af patientrapporterede oplysninger for at opnå dybere indsigt i kombination med datadrevet, digitalt understøttet behandling er nøglen til en effektiv fremtidig levering af sundhedsydelser. ”
Forventninger til 2026
Monsenso forventer en omsætning for 2026 på ca. DKK 11m svarende til en vækst på 24% og driftsresultat (EBIT) på DKK -4m. Forventningerne er forbundet med væsentlige usikkerheder, herunder going concern, som er beskrevet i noterne 2 og 3 til årsregnskabet.
Hovedtal
(‘000 DKK)
2025
2024
Omsætning
8.907
11.165
Primært driftsresultat (EBITDA)
(2.961)
(2.053)
Driftsresultat (EBIT)
(7.582)
(6.481)
Årets resultat
(7.217)
(6.001)
Likvide beholdninger
54
1.861
Aktiver i alt ultimo
13.050
18.490
Egenkapital ultimo
6.976
14.164
Resultat pr. aktie (DKK)
(0,11)
(0,12)
Antal fuldtidsansatte ultimo (FTE)
10
13
CEO Thomas Lethenborg og CFO Robert Højer har optaget en video der uddyber årsrapporten som kan findes her: https://www.monsenso.com/investors/
Ansvarsfraskrivelse
Denne rapport indeholder fremadrettede udsagn, der er baseret på ledelsens nuværende forventninger. Alle udsagn om fremtiden er underlagt iboende risici og usikkerheder, og mange faktorer kan føre til faktiske resultater og udvikling, der afviger væsentligt fra det, der er udtrykt eller underforstået i sådanne udsagn.
Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til:
Selskabet:
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
BestyrelsesformandPeter Mørch EriksenE-mail: petermorcheriksen@outlook.com
Certified Adviser
HC Andersen CapitalBredgade 23, 1260 København K
Vedhæftninger
Download selskabsmeddelelse.pdf
2025 Annual Report.pdf
5.3.2026 08:45:01 CET | Monsenso |
Annual financial report
Company announcement no. 01-2026
Copenhagen, 2026.03.05
Monsenso’s annual report for 2025 was approved by the Board of Directors today.
Performance highlights
The total revenue decreased by 20% to DKK 8,907k (2024: DKK 11,165k)
EBITDA was DKK -2,961k (2024: DKK -2,053k)
Operating profit (EBIT) was DKK -7,582k (2024: DKK -6,481k)
Cash flows from operating activities were DKK -1,490k (2024: DKK -7,033k)
The total equity as of December 31, 2025 amounted to DKK 6,976k (2024: DKK 14,164k)
Total cash and cash equivalents as of December 31, 2025 amounted to DKK 54k (2024 DKK 1,861k)
Business development
The year 2025 offered significant challenges, as it navigated delays in key strategic projects impacting revenue and financial performance. Particularly in Denmark, market conditions hindered progress, with a shift towards proprietary solutions in the public health sector. In Spain, an anticipated project faced delays due to a vendor selection appeal and ultimately resulted in a significantly reduced scope of work.
Despite these hurdles, the company continued to engage in promising projects, and all innovation and research projects are progressing.
Notably, the collaboration on the PhaseV innovation project with prominent partners has an advanced decentralised trials solution, with completed patient recruitment in one study and ongoing recruitment in two other studies. A fully decentralised headache research study based on our platform in collaboration with Lundbeck and Nationalt Videnscenter for Hovedpine has been completed, and the first publications are out.
Additionally, the PERSONAE project, focused on personalized treatment through AI, is moving forward with the randomized controlled trial. The Mentbest project, targeting mental health through an AI-driven self-help tool, is actively recruiting participants across multiple European countries.
We still believe the markets for digital health within mental health and chronic disorders remain attractive, driven by the urge for efficiency in European healthcare systems. As we enter 2026, we see great opportunities to grow the business again powered by a few larger projects.
Thomas Lethenborg, CEO says:
“Digital health is definitely high on the agenda across both public and private providers, research institutions and pharmaceuticals. The realisation that the combination of continuous patient-reported outcomes monitoring for deeper insights and data-driven, blended care is key to efficient future healthcare delivery is growing.”
Outlook for 2026
For 2026, we expect revenue of around DKK 11m, corresponding to 24% growth, with an EBIT of DKK -4m. The expectations are associated with significant uncertainties, including going concern, which are described in notes 2 and 3 to the financial statements.
Key figures
(‘000 DKK)
2025
2024
Revenue
8,907
11,165
EBITDA
(2,961)
(2,053)
EBIT
(7,582)
(6,481)
Profit (loss) for the year
(7,217)
(6,001)
Cash and cash equivalents
54
1,861
Total assets, end of year
13,050
18,490
Equity, end of year
6,976
14,164
Net profit per share (DKK)
(0.11)
(0.12)
End-of-year, number of employees (FTE)
10
13
CEO Thomas Lethenborg and CFO Robert Højer have recorded a video that comments on the annual report. The link is here: https://www.monsenso.com/investors/.
Disclaimer
This report contains forward-looking statements which are based on the current expectations of the management. All statements regarding the future are subject to inherent risks and uncertainties, and many factors can lead to actual results and developments deviating substantially from what has been expressed or implied in such statements.
Any inquiries regarding this notice should be directed to:
Monsenso
CEOThomas LethenborgTel +45 21 29 88 27E-mail: lethenborg@monsenso.com
Chairman of the boardPeter Mørch EriksenE-mail: Petermorcheriksen@outlook.com
Certified Adviser
HC Andersen CapitalBredgade 23, 1260 København K
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
2025 Annual Report.pdf
